Abstracts tagged "DMARDs"

Abstract Number: 478 • 2014 ACR/ARHP Annual Meeting
Adverse Events and Infections in Patients with Rheumatoid Arthritis Treated with Conventional Drugs or Biologic Agents: A Real World Study
Christos E. Lampropoulos¹, Philippos Orfanos², Vasiliki-Kalliopi Bournia³, Theofilos P. Karatsourakis⁴, Clio P. Mavragani⁵, Dimitrios Pikazis⁴, Menelaos N. Manoussakis⁶, Athanasios G. Tzioufas⁴, Haralampos M. Moutsopoulos⁷ and Panayiotis G. Vlachoyiannopoulos³, ¹Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ²Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National University of Athens, Athens, Greece, ³First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ⁴Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ⁵Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, ⁶Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ⁷Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease with joint destruction and permanent disability. Biologic agents (BAs) offer a better outcome when disease is…
Abstract Number: 2902 • 2014 ACR/ARHP Annual Meeting
The Health Status of Patients with Juvenile Idiopathic Arthritis (JIA) Significantly Worsens after Transfer from Pediatric to Adult Care
Kirsten Minden¹, Jens Klotsche², Martina Niewerth², Angela Zink³ and Gerd Horneff⁴, ¹Chidlrens´ hospital, Charité University Medicine, Berlin, Germany, ²Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ³German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany
Background/Purpose A minority of patients with polyarticular JIA enter adulthood in drug free remission. Thus, patients are in need of care beyond adolescence. There is…
Abstract Number: 1527 • 2014 ACR/ARHP Annual Meeting
Efficacy of Biologic Treatments in Early Active Rheumatoid Arthritis: An Indirect Comparison
Laura Sawyer¹, Stacey Chang¹, Alex Diamantopoulos² and Fred Dejonckheere³, ¹Symmetron Limited, London, United Kingdom, ²Symmetron Limited, Herts, United Kingdom, ³F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: To date, no head-to-head trials have been conducted comparing the efficacy of biologic treatments for early active rheumatoid arthritis (ERA). Here, we evaluated the…
Abstract Number: 477 • 2014 ACR/ARHP Annual Meeting
Leflunomide Use Is Not Associated with an Increased Risk of Lung Disease in Rheumatoid Arthritis: A Meta-Analysis of Randomised Controlled Trials
Richard Conway¹, Candice Low², Robert J. Coughlan¹, Martin O'Donnell³ and John J. Carey¹, ¹Rheumatology, Galway University Hospitals, Galway, Ireland, ²Medicine, St. James Hospital, Dublin, Ireland, ³Clinical Research Facility, Galway University Hospitals, Galway, Ireland
Background/Purpose Leflunomide is an effective treatment for rheumatoid arthritis. An association between pulmonary adverse events, in particular interstitial lung disease, and leflunomide use has been…
Abstract Number: 2832 • 2014 ACR/ARHP Annual Meeting
The Effect of Co-Medication with Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs on TNF Inhibitor Drug Survival in Patients with Ankylosing Spondylitis: Results from a Nationwide Prospective Study
Elisabeth Lie^1,2, Lars Erik Kristensen³, Helena Forsblad-d'Elia¹, Johan Askling⁴ and Lennart T. Jacobsson¹, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Section of Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden, ⁴Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose For rheumatoid arthritis it is well established that co-medication (co-med) with methotrexate (MTX) increases the efficacy and drug survival of TNF inhibitors (TNFi), while…
Abstract Number: 1488 • 2014 ACR/ARHP Annual Meeting
Clinical Efficacy of Add-on Iguratimod Therapy in Patients with Active Rheumatoid Arthritis Despite of Methotrexate ~a Multicenter Registry Study~
Yasuhide Kanayama¹, Toshihisa Kojima², Atsushi Kaneko³, Yuji Hirano⁴, Nobunori Takahashi², Shinya Hirabara⁴ and Naoki Ishiguro², ¹Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ²Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan
Background/Purpose Iguratimod (IGU) is a small-molecule antirheumatic drug that was approved in Japan in September 2012. IGU suppressed tumor necrosis factor-alpha-induced production of interleukin (IL)-6,…
Abstract Number: 423 • 2014 ACR/ARHP Annual Meeting
Circulating Anti-Citrullinated Peptide Antibodies and Cytokines As Biomarkers of Response to Disease-Modifying Antirheumatic Drugs Therapy in Early Rheumatoid Arthritis
Mahmood MTM Ally¹, Pieter Meyer², Bridget Hodkinson³, Eustasius Musenge⁴, Gregory Tintinger², Mohammed Tikly⁵ and Ronald Anderson¹, ¹University of Pretoria, Pretoria, South Africa, ²university of pretoria, pretoria, South Africa, ³Rheumatology, University of the Witwatersrand, Johannesburg, South Africa, ⁴University of Witwatersrand, Johannesburg, South Africa, ⁵Rheumatology Wits University, C H Baragwanath Hospital, Johannesburg, South Africa
Background/Purpose Serial measurement of circulating anti-citrullinated peptide antibodies (ACPA) and cytokines is of potential importance in the management of patients with rheumatoid arthritis (RA). However,…
Abstract Number: 2810 • 2014 ACR/ARHP Annual Meeting
Reduced Mortality Risk in Rheumatoid Arthritis: Findings from Two UK Inception Cohorts
Sam Norton¹, Elena Nikiphorou², Lewis Carpenter³, David Walsh^4,5, Patrick Kiely⁶, Josh Dixey⁷ and Adam Young^2,8, ¹Institute of Psychiatry, King's College London, London, United Kingdom, ²School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, ³Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, ⁴Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom, ⁵Rheumatology, Sherwood Forest Hospitals NHS Foundation Trust, Sutton-in-Ashfield, United Kingdom, ⁶Rheumatology Dept, St. Georges Healthcare NHS Trust, London, United Kingdom, ⁷Rheumatology, New Cross Hospital, Wolverhampton, United Kingdom, ⁸Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom
Background/Purpose Rheumatoid arthritis (RA) is associated with a 20 to 30% increased risk of mortality from all-causes compared to the general population. The aim of…
Abstract Number: 1497 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Iguratimod for Rheumatoid Arthritis
Tsuneo Kondo¹, Akiko Shibata¹, Ryota Sakai¹, Kentaro Chino¹, Ayumi Okuyama¹, Hirofumi Takei¹ and Koichi Amano², ¹Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan, ²Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…
Abstract Number: 301 • 2014 ACR/ARHP Annual Meeting
Pregnancies in Females with Juvenile Idiopathic Arthritis (JIA) Who Were Exposed to Biologics and/or Methotrexate – Results from a Biologic Register
Katrin Stüdemann¹, Martina Niewerth¹, Jens Klotsche¹, Angela Zink², Gerd Horneff³ and Kirsten Minden^1,4, ¹Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ³Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴Chidlrens´ hospital, Charité University Medicine, Berlin, Germany
Background/Purpose JIA often continues into adult life and affects about 1 in 1,000 people of childbearing age. Little is known about the impact of JIA…
Abstract Number: 2555 • 2014 ACR/ARHP Annual Meeting
The Effect of Co-Medication with Conventional Synthetic (cs)Dmards on Achieving Low Disease Activity While Persisting on Adalimumab Therapy in Patients with Ankylosing Spondylitis/ Axial Spondylarthritis (AS)– Analysis from the Czech Biologics Registry Attra
Karel Pavelka¹, Jakub Zavada², Marketa Fojtikova³, Sarka Forejtova⁴ and Karel Hejduk⁵, ¹Institute of Rheumatology, Prague, Czech Republic, ²Charles University, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁴Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁵Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
Background/Purpose : The role of combined treatment with csDMARDs and anti-TNF therapy in AS is not well established. Methods: Main goal of this study was…
Abstract Number: 1489 • 2014 ACR/ARHP Annual Meeting
Influences of Disease Activity at the Initiation of Iguratimod, a Small Molecule Antirheumatic Drug, on Efficacy of Iguratimod in Patients with Rheumatoid Arthritis –a Multicenter Registry Study-
Yuji Hirano¹, Toshihisa Kojima², Yasuhide Kanayama³, Shinya Hirabara¹, Nobunori Takahashi², Atsushi Kaneko⁴ and Naoki Ishiguro², ¹Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ²Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan
Background/Purpose: Iguratimod (IGU), known as T-614, is a small-molecule antirheumatic drug developed in Japan and used in Japanese clinical practice since June in 2012. IGU…
Abstract Number: 274 • 2014 ACR/ARHP Annual Meeting
Treatment Prescribing Patterns in a Cohort of Patients with Juvenile Idiopathic Arthritis (JIA). Data from the Childhood Arthritis Prospective Study
Rebecca Davies¹, Roberto Carrasco², Helen Foster³, Eileen Baildam⁴, Alice Chieng⁵, Joyce Davidson⁶, Yiannis Ioannou⁷, Lucy R. Wedderburn⁸, Wendy Thomson⁹, Kimme L. Hyrich¹⁰ and on Behalf Of Childhood Arthritis Prospective Study (CAPS)¹¹, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Newcastle University, Newcastle, United Kingdom, ⁴Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁵Manchester Children's Hospital, Manchester, United Kingdom, ⁶Royal Hospital for Sick Children, Glasgow, United Kingdom, ⁷Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁸Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁹Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ¹⁰Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹¹university of Manchester, Manchester, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a heterogenous disease, classified according to the International League of Associations for Rheumatology (ILAR). Initial treatment is based largely…
Abstract Number: 2565 • 2014 ACR/ARHP Annual Meeting
The Effect of DMARD Co-Therapy on the Clinical Efficacy of Anti-TNF Medications in Patients with Axial Spondyloarthritis
Michael J. Nissen¹, Adrian Ciurea², Juerg Bernhard³, Rudiger Muller⁴, Giorgio Tamborrini⁵, Martin Toniolo⁶, Cem Gabay⁷ and Axel Finckh¹, ¹Rheumatology, Geneva University Hospital, Geneva, Switzerland, ²Gloriastrasse 25, Rheumaklinik, Universitatsspital Zurich, Zurich, Switzerland, ³Rheumatology, Solothurn Hospital, Solothurn, Switzerland, ⁴Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁵Department of Rheumatology and Musculoskeletal Ultrasound, Bethesda Hospital Basel, Basel, Switzerland, ⁶Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁷University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland
Background/Purpose: Randomized clinical trials and current recommendations suggest little role for disease-modifying anti-rheumatic drugs (DMARDs) as co-therapy with anti-TNF (aTNF) agents in patients with axial-spondyloarthritis…
Abstract Number: 1452 • 2014 ACR/ARHP Annual Meeting
Timing of Decisions to Adjust Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting
Yomei Shaw¹, Chung-Chou H. Chang², Marc C. Levesque³, Julie M. Donohue⁴, Kaleb Michaud^5,6 and Mark S. Roberts¹, ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ⁴Health Policy & Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁵National Data Bank for Rheumatic Diseases, Wichita, KS, ⁶Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Current guidelines recommend that rheumatoid arthritis (RA) patients with poor response to their current regimen of disease modifying anti-rheumatic drugs (DMARDs) have therapy adjusted…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].